RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai’s Zai Lab announced its electric field treatment for cancer, Tumor Treating Fields, was designated an Innovative Medical Device in China, which accelerates the approval process. Zai in-licensed greater China rights to the product from Novocare last year, and launched the product in Hong Kong in December as a treatment for glioblastoma multiform under the name Optune. Optune uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth and inducing cancer cell death. Source: China Biotoday